Compare Crispr Therapeutics AG (CRSP) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Union Pacific Corporation — how do they compare? Crispr Therapeutics AG trades at $51.56 (market cap $4.97B), while Union Pacific Corporation trades at $287.89 (market cap $171.17B). The key difference: Union Pacific Corporation is far larger — about 34.4× Crispr Therapeutics AG's market cap, and Union Pacific Corporation pays a 1.91% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | UNP | |
|---|---|---|
Market Cap | $4.97B | $171.17B |
Sector | Health | Industrials |
52-Week High | $76.78 | $289.13 |
52-Week Low | $44.34 | $214.91 |
Enterprise Value | $3.32B | $201.64B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Union Pacific (UNP) trades at $289.13, up 0.76% with a bullish technical signal. The company shows strong profitability with 29.2% net margins and 40.69% ROE, though valuation multiples remain elevated. Recent earnings beat expectations in Q1 2026, and the proposed Norfolk Southern merger represents a significant growth catalyst. Cash flow generation remains robust at $9.29B from operations in 2025.
Outlook remains positive with analyst consensus at Buy and $304.23 price target, though regulatory hurdles for the merger and elevated RSI levels pose near-term risks. The stock offers dividend growth potential with stable operational performance, but faces headwinds from industry consolidation concerns and potential legal liabilities from ongoing class action litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
